Showing stories 1 - 10 of about 66
Is Aegerion Pharmaceuticals, Inc. (AEGR) Now a Sell?
Aegerion Pharmaceuticals Given New $65.00 Price Target at Leerink Swann ... Daily Political
Related articles »
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) had previously reported that patient cost would be between $200,000 and $300,000 annually for Juxtapid.
Aegerion Pharmaceuticals PT Raised to $50.00 at Jefferies Group (AEGR)
Mideast TimeAegerion Pharmaceuticals Given New $65.00 Price Target at Leerink Swann ... Daily Political
Related articles »
PERFORMING BIOTECHNOLOGY and DRUGS COMPANIES: Aegerion ...
Huntington Beach, CA -- (SBWIRE) -- 05/21/2013 -- PSPicks.com provides its subscribers with a free newsletter that reports up to the minute information and exclusive charts on cheap, undervalued, hidden, and undiscovered stocks traded on the NASDAQ, ...
Related articles »
Aegerion Pharmaceuticls Inc.a (NASDAQ:AEGR)'s shares down by 1.56%
Northern, WI 05/17/2013 (usmarketsdaily) - The prices of Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) currently trading at $60.74, down by 1.56%.
Aegerion Pharmaceuticals, Inc. (AEGR) Tops Q1 EPS by 7c
Wall Street Gets It Backward On Amgen Cholesterol Drug Forbes
Related articles »
Aegerion continues to expect total operating expenses, excluding stock-based compensation expense, to be between $75 and $85 million in 2013.
Aegerion Pharmaceuticals Management Discusses Q1 2013 Results - Earnings ...
Seeking AlphaWall Street Gets It Backward On Amgen Cholesterol Drug Forbes
Related articles »
Mid-Day Market Movers: Aegerion Pharmaceuticals, Inc., Cisco Systems, Inc ...
Huntington Beach, CA -- (SBWIRE) -- 05/16/2013 -- PSPicks.com provides its subscribers with a free newsletter that reports up to the minute information and exclusive charts on cheap, undervalued, hidden, and undiscovered stocks traded on the NASDAQ, ...
AEGERION PHARMACEUTICALS INC. : Anne VanLent Appointed to Aegerion ...
CAMBRIDGE, Mass., April 29, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, ...
Related articles »
Aegerion Pharmaceuticals Announces Presentation at the Needham Healthcare ...
CAMBRIDGE, Mass., April 25, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often ...
Related articles »
Aegerion Pharmaceuticals Earnings Preview: Can This Streak Finally End?
Aegerion Pharmaceuticals (NASDAQ:AEGR) will report earnings before markets open on Tuesday, April 30th. Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company researches small-molecule therapeutics for cardiovascular and ...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
CAMBRIDGE, Mass., May 3, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating ...
Related articles »
Aegerion Pharmaceuticals PT Raised to $65.00 at Leerink Swann (AEGR)
Separately, analysts at Jefferies Group raised their price target on shares of Aegerion Pharmaceuticals from $46.00 to $50.00 in a research note to investors on Friday, May 10th.